In July 2026, Nature Medicine published the largest genetic study of fibromyalgia ever conducted: 2.5 million people, six countries, 26 risk variants. The headlines wrote themselves. “Fibromyalgia gene found.” “Huntington’s drug could treat chronic pain.”
But buried past the abstract is a figure that should reshape how you think about this condition. Heritability came in at roughly 10%.
Hold onto that, because it changes everything about how the rest of the paper should be read.
What 10% actually tells you
Ten percent means genes explain about a tenth of the risk. The authors are clear on this themselves: the variants create a predisposition, but something has to activate it. They list the usual suspects: injury, surgery, infection, grief, sustained stress.
So the honest summary isn’t “fibromyalgia is genetic.” It’s “some nervous systems are wired to be more reactive, and under enough pressure that reactivity gets stuck on.” The gun is loaded by inheritance. The trigger is pulled by life.
That distinction matters because it decides where you put your effort. If the condition were 100% genetic, waiting for a drug would be rational. At 10%, waiting means ignoring the 90% that is still in play.
What the study genuinely settles
Before the critique, give credit where it’s due. For decades patients have been told their pain was anxiety, depression, hypervigilance, or simply ageing. This paper puts that argument to bed.
When the researchers checked where the 26 risk genes were most active across 20 million cells, the answer wasn’t immune tissue, joints or muscle. It was neurons. Fibromyalgia is a disorder of pain processing, not of the tissue being processed. That’s why bloods come back normal and scans look clean: standard pathology isn’t measuring the thing that’s wrong.
Two further results deserve attention. Men carry the same genetic risk as women, despite women being diagnosed three times as often, so the gap is hormonal, environmental or diagnostic, not inherited. And the genetic overlap with irritable bowel syndrome was 0.7, an unusually strong correlation.
The finding everyone skipped
That IBS number isn’t a coincidence. Gene activity was also enriched in enteric neurons, the half-billion nerve cells lining the gut.
Read plainly: the same vulnerability that sensitises pain circuits in the brain and spinal cord is expressed in the digestive tract. Fibromyalgia and IBS aren’t two conditions that happen to co-occur. They look like one nervous-system trait showing up in two places.
If your pain flares when your gut is bad, you were never imagining the link. An irritated enteric nervous system sends a constant stream of noise upstream to a brain already turned up too loud.
Why the headline went elsewhere
Look at the funding disclosures. The Icelandic sequencing was done by deCODE, owned by Amgen. Several authors are Amgen employees. Other cohorts list Novo Nordisk Foundation and life-science consortium support.
None of that fabricates the data. Studies of this size are almost always industry-funded because almost no one else can pay for them. But funders shape questions. If your business is drug development, you spotlight the druggable receptor (GPR52, already in a Huntington’s pipeline) and spend little time on sleep, stress physiology or the microbiome, because none of those can be patented.
The data is solid. The lens is narrow.
From “all in your head” to “all in your genes”
There’s a bitter symmetry here. The system that dismissed this pain as psychological is now preparing to explain it as genetic destiny. Both framings leave you passive: one tells you to think differently, the other tells you to wait.
A more useful question is: what is keeping this nervous system sensitised right now, and which of those inputs can be changed?
Clinically, that usually comes down to the same territory the study points at. Sleep quality, since non-restorative sleep is one of the most reliable pain amplifiers. Autonomic balance and the inhibitory side of the nervous system: GABA pathways, magnesium, breathing, graded movement. Neuroinflammation and mitochondrial function, which can be measured with functional testing rather than guessed at. And the gut: dysbiosis, SIBO, barrier integrity, food triggers.
No single one of these is a cure. That is precisely the point. A multi-input problem needs a multi-input response.
Sensitisation is a state, not a structure. States can be changed. The study didn’t give you a diagnosis to live with. It gave you a map of where to look.
Curious about naturopathic care?
If this gave you a clearer sense of what a naturopathic consultation looks like, the video above goes through it in my own words. Whatever path you choose, the throughline is the same: a holistic look at your whole system, and a plan built around you.
Take the Next Step
If you’re tired of guessing what’s wrong and want real answers for your health challenges, the right tests can make all the difference. A skilled practitioner can help you navigate the results and build a tailored path to recovery.
Ready to reclaim your energy? Schedule a consultation with a functional medicine expert or continue learning about your options to take control of your health.